Search

Your search keyword '"Derosa, Lisa"' showing total 217 results

Search Constraints

Start Over You searched for: Author "Derosa, Lisa" Remove constraint Author: "Derosa, Lisa" Search Limiters Full Text Remove constraint Search Limiters: Full Text
217 results on '"Derosa, Lisa"'

Search Results

1. Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance

2. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance

4. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

5. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma

6. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

7. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

8. Melanoma and microbiota: Current understanding and future directions

9. Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

10. Benzodiazepines compromise the outcome of cancer immunotherapy.

11. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.

12. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

13. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

14. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

15. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease

16. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

17. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

18. Multifaceted modes of action of the anticancer probiotic Enterococcus hirae

19. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

20. State of the art and the future of microbiome-based biomarkers:a multidisciplinary Delphi consensus

21. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

23. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer

28. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

29. Immunodynamics of explanted human tumors for immuno‐oncology

31. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies

33. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

34. Cancer induces a stress ileopathy depending on B-adrenergic receptors and promoting dysbiosis that contribute to carcinogenesis

35. Cancer Induces a Stress Ileopathy Depending on beta-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis

37. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in advanced non-small cell lung cancer patients

39. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

40. Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients

41. Cancer induces a stress ileopathy depending on B-adrenergic receptors and promoting dysbiosis that contribute to carcinogenesis

42. Immunodynamics of explanted human tumors for immuno‐oncology

43. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

44. Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites

45. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade

46. Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma

49. Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

50. Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

Catalog

Books, media, physical & digital resources